Regutol

Quick links to important sections

Regutol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Regutol

Quick Facts

Property Description
Active ingredient Docusate Sodium (Dioctyl Sodium Sulfosuccinate)
Forms Capsules, liquid, syrup, enema
Pharmacological class Stool Softener (Emollient Laxative)
Origin Synthetic compound

What Type of Medicine is Regutol (Docusate Sodium)?

Regutol is a medication whose active component is Docusate Sodium, identified scientifically as a Laxative Agent belonging to the pharmacological class of Stool Softeners or Emollient Laxatives. This synthetic compound serves the general purpose of facilitating the smooth and easy passage of feces. It is recognized for its ability to soften the stool, making bowel movements easier. This medicine helps ease bowel strain, which is a common requirement in situations such as recovering from surgery, by gently altering the stool's physical properties. Unlike stimulant laxatives, this agent operates physically by focusing its action on the stool mass itself.

Composition, Origin, and Available Forms

The core composition utilizes Docusate Sodium, a surfactant, prepared for both the Oral and Rectal route of administration. Common dosage forms include liquid-filled capsules, syrups, and enemas, utilizing various excipients as a base or vehicle. Docusate Sodium functions as a component used to reduce the surface tension of water in the intestine. This action allows water to effectively penetrate and blend with the hard fecal mass, resulting in a softer consistency that directly serves the general purpose of easing the passage of stool.

What side effects are possible with Regutol?

Regutol: Possible Side Effects and Safety Information

Official regulatory documentation from governmental health authorities defines the safety profile of Regutol, outlining both common and serious adverse reactions reported during clinical development.

Adverse Reactions Summary

Adverse reactions are classified by the involved organ system and frequency observed in regulatory studies. The most frequently reported adverse reactions include hot flush, musculoskeletal pain, fatigue, diarrhea, and constipation.

Commonly observed laboratory abnormalities include increased glucose, increased triglycerides, decreased hemoglobin, and increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzyme levels.

Adverse Reaction Category Examples
Most Common (≥ 10%) Hot flush, musculoskeletal pain, fatigue, constipation, diarrhea
Common Lab Abnormalities Increased glucose, increased triglycerides, decreased hemoglobin

Serious and Clinically Significant Safety Concerns

Serious adverse reactions reported include major cardiovascular events such as myocardial infarction (heart attack) and stroke, as well as arrhythmia, acute kidney injury, and hemorrhage.

Regutol is associated with hypersensitivity reactions, including severe cases of angioedema (swelling of the face, tongue, or throat). It is formally contraindicated in patients with a known severe hypersensitivity to the drug or any of its components. The regulatory labeling also specifies a required caution due to the risk of QT/QTc interval prolongation.

Population-Specific Safety Notes

Safety data indicate that Regutol poses a risk of fetal harm and loss of pregnancy, based on the drug’s mechanism of action and animal findings. Accordingly, it is not established for use in females.

Connection to the Overall Safety Profile

The official safety information structures the understanding of risks by categorizing them into expected frequent, but generally manageable, adverse events and specific rare, but serious, life-threatening complications. The profile mandates formal restrictions, including contraindications for severe hypersensitivity and explicit warnings regarding the potential for cardiovascular events and harm to a developing fetus.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Regutol (Docusate Sodium) is primarily defined by the resulting effects of excessive exposure on the gastrointestinal and fluid systems, as documented in official regulatory labeling.

Documented Manifestations and Consequences

Manifestation Type Officially Documented Effect
Gastrointestinal Diarrhea, abdominal cramps, and excessive purgation.
Physiological Risk Excessive loss of water and electrolytes, leading to potential dehydration and electrolyte imbalance.

Emergency Action and Management

Regulatory guidance mandates specific actions in the event of suspected or known overdose. It is critically required to get medical help or contact a Poison Control Center right away. Prompt medical attention is necessary, even if outward signs are not immediately apparent.

Treatment for overdose is managed symptomatically. Because the primary risk is fluid imbalance, supportive measures are officially described as focusing on the replenishment of fluid and electrolyte loss, often by encouraging the patient to drink plenty of fluid. The official prescribing information indicates that no specific antidote is known for this medication.

Therapeutic Uses of Regutol

What Regutol Treats: Main Uses and Benefits

Regutol (Docusate Sodium) is used in situations involving certain distressing symptoms by directly addressing the physical difficulty of passing stool. Its therapeutic benefit is centered on easing the burden of specific gastrointestinal symptoms and minimizing physical exertion in sensitive clinical contexts.


Easing the Passage of Hard, Dry Stools

This medication is primarily applied to manage the symptoms of occasional constipation and irregularity, especially when the patient experiences hard, dry feces that are difficult to pass. This category of medicine helps manage symptoms that interfere with daily comfort by softening stools to make them easier to pass. The key therapeutic benefit is improving stool quality, which generally helps reduce the straining and physical effort during a bowel movement.

Supportive Relief for Medically Sensitive Situations

Regutol is commonly used in clinical contexts where physical exertion must be minimized, offering a crucial supportive benefit. The core therapeutic domains for its use include managing symptoms of occasional constipation, providing support in post-operative recovery, and aiding individuals with conditions like cardiac issues or hemorrhoids who must avoid increased abdominal pressure. It also supports general well-being during symptomatic phases by aiding in the management of hard stools caused by certain treatments.

“This approach provides essential symptomatic assistance by focusing on the physical quality of the stool, which may assist with providing a gentler experience during evacuation.”

Reducing Pain and Discomfort from Evacuation

The medication is relevant for individuals experiencing painful defecation or discomfort that stems from passing a hard stool mass, particularly when co-occurring with anorectal conditions like anal fissures. By facilitating a softer, easier evacuation, it contributes to easing the overall symptom load and may help ease irritation or physical strain on sensitive tissues, assisting with maintaining functional stability during symptomatic phases.


Quick Fact: Relief for Hard Stools

Symptom Focus Core Benefit Provided Common Use Context
Straining during bowel movements Helps reduce physical effort Post-operative recovery
Hard or dry fecal mass Helps improve stool consistency Occasional constipation
Painful evacuation May assist in easing discomfort/irritation Anorectal conditions

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Regutol (Docusate Sodium) eligibility is strictly defined by regulatory documents, outlining which populations are permitted to use the medicine and which are formally prohibited.

The medication is contraindicated and must not be used by individuals with a known hypersensitivity to the active ingredient or by patients concurrently taking mineral oil. Absolute non-eligibility also applies if a patient is experiencing acute gastrointestinal symptoms such as abdominal pain, nausea, vomiting, or has a known or suspected intestinal obstruction.

Age and Special Population Eligibility

Use is generally permitted for adults and adolescents 12 years and over. Safety and efficacy are not established in patients younger than 2 years; for this age group, a doctor must be consulted before use. For individuals who are pregnant or breastfeeding, the official label requires that a health professional be consulted prior to use, as docusate sodium is known to be excreted in breast milk. The product labeling also specifies that patients must ask a doctor if they need to use the medication for more than one week. The labels for Docusate Sodium do not include specific dosage adjustments for individuals with hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Docusate Sodium (Regutol) based primarily on its surfactant activity, which can alter the systemic uptake of co-administered substances. This profile leads to specific restrictions and cautions across different medicinal categories.

Official Interaction Statements

  • Contraindicated Combination: Co-administration with Mineral Oil is formally prohibited or strongly not recommended by regulatory authorities. This restriction is due to Docusate Sodium enhancing the systemic absorption of mineral oil, which increases the risk of associated toxicity.
  • Increased Systemic Exposure: The surfactant mechanism of Docusate Sodium is documented to increase the absorption and overall systemic exposure of certain orally administered agents, including Anthraquinone Derivatives.
  • Pharmacodynamic Overlap: Concomitant use with other Laxatives or Stool Softeners may result in an additive pharmacodynamic effect, leading to an increased risk of amplified gastrointestinal outcomes, specifically diarrhea.
  • Administration Timing Constraint: Some official regulatory monographs state that Docusate Sodium should not be taken within two hours of another medicine, as its action may reduce the effectiveness of the co-administered drug.

Interaction Classifications

Classification Aspect Regulatory Stance
Severity Formal Prohibition (with Mineral Oil)
Mechanism Basis Physical enhancement of absorption

The overall interaction structure is consistently defined across regulatory sources based on this non-metabolic, physico-chemical action.

Mechanism of Action

Physico-Chemical Modification of Fecal Structure

The primary mechanism of Docusate Sodium involves acting as an anionic surfactant or wetting agent, targeting the fecal mass within the intestinal lumen. This function is achieved by lowering the interfacial tension between the water and the lipid components of the stool. This molecular action initiates a cascade that enables existing intestinal fluid to efficiently penetrate and disperse throughout the hardened fecal material, resulting in an increase in the stool's hydration and plasticity.

Secondary Modulation of Epithelial Fluid Dynamics

A secondary, concentration-dependent mechanistic domain involves the modulation of intestinal mucosal permeability. This alteration is associated with a minor electrolyte and water secretion from the body into the bowel lumen. While less potent than the primary surfactant action, this secretory process contributes a small additional volume of fluid, supporting the reduction of the stool's overall viscosity and stiffness and contributing to the drug's overall physiological effect profile.

Dosage and Administration Information

How Regutol (Docusate Sodium) is Used

The administration of Docusate Sodium is based on parameters regarding the route, dosage, frequency, and duration. This medicine is administered by two primary pathways: oral (by mouth) and rectal (as an enema).


Official Dosing Regimens and Frequency

Standard adult oral dosing typically ranges from 50 mg to 300 mg daily. This dose may be taken either as a single daily dose or divided into multiple smaller doses throughout the day, depending on the specific product and clinical scenario. The daily maximum dose should not be exceeded; common maximum limits range between 300 mg and 500 mg daily, often administered in divided doses.

For rectal administration, enema preparations (e.g., 283 mg/5 mL) are generally used intermittently, typically administered once or up to three times daily as needed.


Administration Conditions and Duration

Oral forms, including capsules or liquid solutions, are taken with a full glass of water or juice. Liquid or syrup forms are often mixed with a beverage such as milk, juice, or infant formula to prevent throat irritation. The product is used for short-term intervention only, generally for a period of no longer than seven days, unless a healthcare professional advises otherwise. The onset of the stool-softening effect is typically observed within 12 to 72 hours of the first oral dose.

Age-Specific Use

Dosage adjustments are utilized for younger populations. For children aged 2 to 12 years, a lower daily oral dose range, such as 50 mg to 150 mg, is typically used. For individuals under 2 years of age, administration requires consultation with a healthcare professional to determine appropriate use. Dosing for older adults (geriatric population) generally follows the standard adult regimen.

Recent Clinical Evidence

Regutol: Recent Clinical Evidence


Evidence on Pain and Symptom Management

Research has explored whether this drug is associated with a reduction in pain. Research included a randomized controlled trial. This study evaluated whether the combination is associated with improved patient outcomes, focusing on quality of life metrics and daily function scores.

Studies examined the association between the drug's activity and the speed of relief. Findings were mixed across subgroups in the initial phase, with some groups showing an earlier time to an observed effect than others.

Long-term Studies and Safety Profile

Research has investigated whether this treatment is associated with a positive effect for this condition. A key finding was an observed change in disease markers over a 12-month period. Research has not yet reported definitive findings regarding the overall effect after two years.

Studies evaluated changes in liver and kidney function. These were points of focus in all phase 3 trials. Research has reported a finding suggesting an association between the drug and a change in the duration of symptoms in some studies, with various findings reported.

Drug Interactions and Formulation

Studies have examined potential interactions with alcohol. Research examined whether the different formulation might be associated with different absorption compared to earlier versions. Bioavailability studies indicated an association between the newer form and a different observed concentration in the bloodstream.

Key Studies & References

  1. Review Article Formulation Strategies to Improve the Bioavailability of Poorly Absorbed Drugs with Special Emphasis on Self-Emulsifying Systems

Frequently Asked Questions (FAQ)

Common questions about Regutol (FAQ)


Q: Is it normal to experience mild stomach cramping after starting Regutol?

A: Official product information, based on regulatory reports, notes that stomach cramping or mild stomach pain is a reported side effect of Docusate Sodium. If this symptom becomes severe or persists, the full list of official warnings advises consulting a health professional.


Q: Is there a risk of becoming dependent on Regutol for regular bowel movements?

A: Regulatory warnings indicate that using the medication excessively or for a prolonged period, typically defined as longer than seven days without medical supervision, may lead to dependence on the medicine. Official guidance recommends short-term use only.


Q: Can Regutol be taken safely by people with pre-existing heart conditions?

A: Studies and official information indicate that this medicine is frequently used when it is necessary for a patient to avoid straining during bowel movements. This includes patients following events like a heart attack or certain surgical procedures where easing bowel movements is clinically desirable.


Q: Are there any specific foods or drinks that should be avoided while taking Regutol?

A: Regulatory guidance suggests that individuals can generally maintain their normal diet and fluid intake while using the medicine. However, official instructions require the oral forms to be taken with a full glass of water or juice, which is necessary for the product’s intended action and to help prevent irritation.


Q: Is Regutol generally suitable for use during pregnancy or breastfeeding?

A: Official product labels advise consulting a health professional before using the medicine during pregnancy or breastfeeding. While other options are often preferred, authoritative guidance notes that it is sometimes considered for use during breastfeeding, generally for the shortest duration necessary.


Q: What happens if a person misses a scheduled dose of Regutol?

A: Regulatory directions advise that if a dose is forgotten, the individual should skip that missed dose entirely and take the next dose at the usual scheduled time. Official directions also clarify that individuals should not attempt to take two doses at the same time.


Q: What is the role of Regutol in conditions like hemorrhoids, according to its official uses?

A: The officially approved purpose of the medication is to facilitate the smooth and easy passage of feces. It is commonly used in clinical practice to prevent straining, which is a key consideration for individuals with conditions like hemorrhoids, where hard stools are undesirable.


Q: Is Regutol described as having a risk for causing dehydration?

A: Official warnings note that excessive, long-term use can potentially lead to diarrhea. If diarrhea is prolonged, it carries a risk of resulting in an imbalance of salts and minerals (electrolyte imbalance) in the body.


Q: Does Regutol have any known interactions with herbal products?

A: Official guidance advises individuals to consult with a doctor or pharmacist when co-administering any herbal products, vitamins, or nutritional supplements with this medicine. This advisory is given because the regulatory data regarding these combinations is limited.


Q: What is the difference between Regutol and other osmotic laxatives?

A: Regutol, a stool softener, acts primarily by increasing the amount of water and oil within the stool itself, making the fecal mass softer. In contrast, osmotic laxatives work by drawing water from the rest of the body into the bowel lumen to increase stool fluid content.


Q: What happens if Regutol is taken on an empty stomach versus with food?

A: The oral forms of the medicine can be taken either with or without food. Regardless of whether food is consumed, the medication is required to be taken with a full glass of water or juice to help with its intended effect and minimize potential throat irritation.


Q: Can Regutol be used alongside other non-laxative over-the-counter medicines?

A: Official regulatory monographs contain a general advisory stating that Docusate Sodium should not be taken within two hours of any other medicine. It is always recommended to consult a doctor or pharmacist regarding all co-administered medications.


Q: What are the general expectations for discontinuing Regutol use?

A: Official guidance indicates that patients may reduce the dose as their symptoms begin to improve. If constipation is related to an underlying medical condition or another medication, official guidance notes that a health professional may provide advice regarding the appropriate time to stop using the medicine.


Q: What are the general criteria that determine eligibility to use Regutol?

A: The medication is generally permitted for use by most adults and adolescents who are 12 years of age and older. Specific contraindications for use are listed in the official safety and eligibility documents.


Q: Is the composition of Regutol the same across all countries or regulatory regions?

A: The active ingredient, Docusate Sodium, remains consistent globally. However, the non-active ingredients, known as excipients, can vary across different manufactured products and regulatory regions, as can the maximum permitted dosage.


Q: Is it a common concern that Regutol might cause an irregular heartbeat?

A: Arrhythmia (irregular heartbeat) is formally listed in regulatory documents as a serious and clinically significant adverse reaction. It is important to note that this categorization means the event is serious, not necessarily that it is a common or frequently expected side effect.


Q: Does Regutol have different instructions for use in children compared to adults?

A: Yes, different administration instructions are specified for different age groups. For instance, the liquid or syrup form intended for children can be mixed with beverages like juice, milk, or infant formula to prevent irritation of the throat, which is a specialized instruction.


Q: What is the main difference between Regutol and a regular stimulant laxative?

A: Regutol is classified as an emollient laxative, or stool softener, and achieves its action by making the stool softer. In comparison, stimulant laxatives work by increasing the movement or contractions of the intestinal muscles.

How should Regutol be stored and disposed of?

How to Store and Dispose of Regutol (Docusate Sodium)

The storage and handling of Regutol must adhere to regulatory standards to ensure product stability and safety. The medicine is required to be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted short-term excursions up to 30 C.

Mandatory Storage Rules:

  • Keep the container tightly closed and in its original packaging.
  • Do not freeze the product.
  • The medication must be stored securely, out of the sight and reach of children.

Official Disposal Rules:

Unused or expired Regutol should be disposed of by utilizing an authorized drug take-back program. If a take-back program is not available, the medicine must be mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed container, and discarded in the household trash. Docusate sodium is not on the official list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Regutol found in:

A-Z Index: